$6.060
-0.249 (-4.11%)終値時点
QUIT の収益性とマージン
Evaluating the bottom line, Achieve Life Sciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -104.23%, provide a clear picture of how effectively QUIT converts its operational activities into shareholder value.
QUIT の同業比較
In the context of the broader market, QUIT competes directly with industry leaders such as IMMX and OLMA. With a market capitalization of $666.78M, it holds a leading position in the sector. When comparing efficiency, QUIT's gross margin of N/A stands against IMMX's N/A and OLMA's N/A. Such benchmarking helps identify whether Achieve Life Sciences, Inc. is trading at a premium or discount relative to its financial performance.
Achieve Life Sciences, Inc. の財務パフォーマンス
BDJ has demonstrated robust financial performance with a 1-year change of +8.67% and a year-to-date change of +2.77%, reflecting positive momentum in its price.
Financials
関連記事
- How to Invest in IPOs: What SpaceX, Cerebras and the Anthropic Debut Teach Investors in 2026How to invest in IPOs as Anthropic lists: how retail allocations work, what IPO data show about returns, SpaceX and Cerebras lessons, lockups and index rules.
- Is the Stock Market Overvalued? Why CAPE Says Yes and the Forward P/E Says Not So FastIs the stock market overvalued? The CAPE is near 39 but the forward P/E is 17.7. What each measure says, the bond yield test, and how to invest in late 2026.
- High Yield Bonds in 2026: What CCC Credit Stress Means for Income Investors and StocksHigh yield bonds pay about 8% in 2026, but CCC spreads have blown out. Learn what credit spreads signal for stocks and how to invest in junk bonds wisely.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。